241 related articles for article (PubMed ID: 34737945)
1. Camrelizumab Plus Sorafenib
Liu Q; You N; Li J; Wu K; Peng X; Wang Z; Wang L; Zhu Y; Zheng L
Front Oncol; 2021; 11():694409. PubMed ID: 34737945
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis.
Qin J; Huang Y; Zhou H; Yi S
Front Oncol; 2022; 12():807102. PubMed ID: 35463356
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study.
Zhu D; Ma K; Yang W; Zhou HF; Shi Q; Ren JW; Xie YG; Liu S; Shi HB; Zhou WZ
Front Oncol; 2022; 12():1057560. PubMed ID: 36439471
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study.
Wei F; Huang Q; He J; Luo L; Zeng Y
Cancer Manag Res; 2021; 13():4233-4240. PubMed ID: 34079375
[TBL] [Abstract][Full Text] [Related]
5. The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC.
Sun T; Ren Y; Sun B; Chen L; Zhu L; Zhang L; Zheng C
J Hepatocell Carcinoma; 2023; 10():447-457. PubMed ID: 36960308
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study.
You R; Xu Q; Wang Q; Zhang Q; Zhou W; Cao C; Huang X; Ji H; Lv P; Jiang H; Lu Y; Jin Y; Li Y; Cheng L; Wang W; Xu H; Zhu X; Yin G
Front Oncol; 2022; 12():816198. PubMed ID: 35982962
[TBL] [Abstract][Full Text] [Related]
7. Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center.
Ju S; Zhou C; Yang C; Wang C; Liu J; Wang Y; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
Front Oncol; 2021; 11():835889. PubMed ID: 35174073
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC.
Li T; Guo J; Liu Y; Du Z; Guo Z; Fan Y; Cheng L; Zhang Y; Gao X; Zhao Y; He X; Wu W; Gao N; Wu Y; Li J; Zhang Y; Kang W; Cai Z; Wang W; Li X; Zan Y; Nguyen MH; Ji F
Cancer Immunol Immunother; 2023 Jul; 72(7):2137-2149. PubMed ID: 36840762
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study.
Qiu Z; Shen L; Jiang Y; Qiu J; Xu Z; Shi M; Yu Z; Ma Y; He W; Zheng Y; Li B; Wang G; Yuan Y
Ann Transl Med; 2021 Feb; 9(4):283. PubMed ID: 33708910
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study.
Chen SC; Huang YH; Chen MH; Hung YP; Lee RC; Shao YY; Chao Y
BMC Cancer; 2022 Jan; 22(1):55. PubMed ID: 35016637
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery.
Wang X; Cao W; Qiu Y; Ji H; Yuan J; Wu W; Liu F; Feng L; Ding R; Li X; Tao K
Front Oncol; 2023; 13():1174999. PubMed ID: 38162488
[TBL] [Abstract][Full Text] [Related]
12. Survival Benefit of Experience of Liver Resection for Advanced Recurrent Hepatocellular Carcinoma Treated with Sorafenib: A Propensity Score Matching Analysis.
Hsueh KC; Lee CC; Huang PT; Liang CY; Yang SF
Curr Oncol; 2023 Mar; 30(3):3206-3216. PubMed ID: 36975456
[TBL] [Abstract][Full Text] [Related]
13. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
[TBL] [Abstract][Full Text] [Related]
14. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
15. Combination of Sorafenib, Camrelizumab, Transcatheter Arterial Chemoembolization, and Stereotactic Body Radiation Therapy as a Novel Downstaging Strategy in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Case Series Study.
Huang Y; Zhang Z; Liao W; Hu K; Wang Z
Front Oncol; 2021; 11():650394. PubMed ID: 34408974
[TBL] [Abstract][Full Text] [Related]
16. Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China.
Liu H; Qin X; Xu Z; Wu M; Lu T; Zhou S; Yao N; Liu S; Shao Y; Han Z
Front Genet; 2022; 13():1000448. PubMed ID: 36160021
[No Abstract] [Full Text] [Related]
17. Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis.
Chen S; Shi M; Shen L; Qi H; Wan W; Cao F; Xie L; Wu Y; Chen G; Mo J; Zhu G; Ye D; Zhang Y; Feng Z; Xu L; Fan W
Int J Hyperthermia; 2020; 37(1):384-391. PubMed ID: 32323585
[No Abstract] [Full Text] [Related]
18. Sorafenib Combined with Chemoembolization for Locally Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score Analysis.
Kim GH; Choi SL; Kim JH; Shim JH; Alali M; Kim N
Life (Basel); 2021 Oct; 11(10):. PubMed ID: 34685437
[TBL] [Abstract][Full Text] [Related]
19. Comparable effects of Jiedu Granule, a compound Chinese herbal medicine, and sorafenib for advanced hepatocellular carcinoma: A prospective multicenter cohort study.
Zhao HT; Meng YB; Zhai XF; Cheng BB; Yu SS; Yao M; Yin HX; Wan XY; Yang YK; Liu H; Shen F; Ling CQ
J Integr Med; 2020 Jul; 18(4):319-325. PubMed ID: 32532615
[TBL] [Abstract][Full Text] [Related]
20. Transarterial Chemoembolization (TACE) Combined with Sorafenib
Ren B; Wang W; Shen J; Li W; Ni C; Zhu X
J Cancer; 2019; 10(5):1189-1196. PubMed ID: 30854128
[No Abstract] [Full Text] [Related]
[Next] [New Search]
